SELLAS Life Sciences Group, Inc. Business Acquisition, Pro Forma Earnings Per Share, Diluted
SELLAS Life Sciences Group, Inc. (SLS) reported Business Acquisition, Pro Forma Earnings Per Share, Diluted of $5.15 per share for the 3-month period ending 2017-09-30, per its 10-K filed 2019-03-22.
Discontinued › Income Statement › Earnings Per Share
us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted · last filed 2019-03-22
- SELLAS Life Sciences Group, Inc. business acquisition, pro forma earnings per share, diluted for the quarter ending 2017-09-30 was $5.15.
- SELLAS Life Sciences Group, Inc. business acquisition, pro forma earnings per share, diluted for the quarter ending 2017-06-30 was -$3.43.
- SELLAS Life Sciences Group, Inc. business acquisition, pro forma earnings per share, diluted for the quarter ending 2017-03-31 was -$1.87.
| Period end | Business Acquisition, Pro Forma Earnings Per Share, Diluted 3 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 3 month as first filed | Business Acquisition, Pro Forma Earnings Per Share, Diluted 6 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 9 month |
|---|---|---|---|---|
| 2017-09-30 | $5.15 10-K · filed 2019-03-22 | -$1.61 10-Q · filed 2018-11-14 | $4.92 10-Q · filed 2018-11-14 | |
| 2017-06-30 | -$3.43 10-Q · filed 2018-08-14 | -$5.93 10-Q · filed 2018-08-14 | ||
| 2017-03-31 | -$1.87 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |